Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey

Su, Jinming; Jia, Zhenwei; Wang, Xinwei; Qin, Fengxiang; Chen, Rongfeng; Wu, Yuting; Lu, Binfeng; Lan, Chunlin; Qin, Tongxue; Liao, Yinlu; Shi, Minjuan; Liao, Yulin; Pan, Peijiang; Li, Ye; Jiang, Junjun; Liang, H.

doi:10.1186/s12879-022-07452-w

Cited by 14 publications

(18 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…What's more, 74.8% of the vaccinated patients did not want to receive another dose of COVID-19 vaccine mainly because of safety concerns. This is consistent with results from the general population and other population groups (24)(25)(26)(27). According to a survey study in Poland, 49.2% of the participants refused to receive a booster dose because of side effects experienced after previous doses, and 22.4% because of safety uncertainties (28).…”

Section: Discussionsupporting

confidence: 87%

COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionBreast cancer is the most prevalent malignancy in patients with coronavirus disease 2019 (COVID-19). However, vaccination data of this population are limited.MethodsA cross-sectional study of COVID-19 vaccination was conducted in China. Multivariate logistic regression models were used to assess factors associated with COVID-19 vaccination status.ResultsOf 2,904 participants, 50.2% were vaccinated with acceptable side effects. Most of the participants received inactivated virus vaccines. The most common reason for vaccination was “fear of infection” (56.2%) and “workplace/government requirement” (33.1%). While the most common reason for nonvaccination was “worry that vaccines cause breast cancer progression or interfere with treatment” (72.9%) and “have concerns about side effects or safety” (39.6%). Patients who were employed (odds ratio, OR = 1.783, p = 0.015), had stage I disease at diagnosis (OR = 2.008, p = 0.019), thought vaccines could provide protection (OR = 1.774, p = 0.007), thought COVID-19 vaccines were safe, very safe, not safe, and very unsafe (OR = 2.074, p < 0.001; OR = 4.251, p < 0.001; OR = 2.075, p = 0.011; OR = 5.609, p = 0.003, respectively) were more likely to receive vaccination. Patients who were 1–3 years, 3–5 years, and more than 5 years after surgery (OR = 0.277, p < 0.001; OR = 0.277, p < 0.001, OR = 0.282, p < 0.001, respectively), had a history of food or drug allergies (OR = 0.579, p = 0.001), had recently undergone endocrine therapy (OR = 0.531, p < 0.001) were less likely to receive vaccination.ConclusionCOVID-19 vaccination gap exists in breast cancer survivors, which could be filled by raising awareness and increasing confidence in vaccine safety during cancer treatment, particularly for the unemployed individuals.

show abstract

Section: Discussionsupporting

confidence: 87%

COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Those who showed positive attitude towards the vaccine, have greater confidence in the vaccine, have better perceived behaviour to take up the vaccination and received other vaccinations in the past 3 years were more vaccine‐accepting [20, 22], whereas people with negative attitudes towards COVID‐19 vaccination, those who generally refused vaccine, those viewing vaccines as unsafe and ineffective for HIV patients and people who had concerns about side effects were less likely to accept COVID‐19 vaccination [19, 22, 23].…”

Section: Resultsmentioning

confidence: 99%

COVID‐19 vaccine acceptance among people living with HIV: A systematic review and meta‐analysis

Ejamo,

Legese,

Tesfaye

et al. 2023

Tropical Med Int Health

View full text Add to dashboard Cite

Objective: To assess coronavirus disease 2019 (COVID-19) vaccine acceptance among people living with HIV (PLHIV) worldwide. Methods: We searched MEDLINE, PSYINFO, CINHAL, Scopus and EMBASE databases and other sources including free Google search and subject-specific journals from January 2020 to September 2021. The study population included adults (aged 18+ years) living with HIV and evaluated for COVID-19 vaccine acceptance. A random effect meta-analysis model was used to estimate the pooled COVID-19 vaccine acceptance rate. Subgroup analyses were performed, and factors associated with COVID-19 vaccine hesitancy underwent narrative analysis. Of 558 initial records, 14 studies were eligible for review. Results: The overall pooled COVID-19 vaccine acceptance rate among adult PLHIV was 62% (95% confidence interval [CI], 56%-69%). In subgroup analysis, the estimated pooled COVID-19 vaccine acceptance rate was higher in high-income countries: 63% (95% CI, 55%-70%) versus 62% (95% CI, 54%-71%) in low-and middle-income countries, and in studies conducted in 2022 (66% [95% CI, 58%-75%]) than in studies conducted in 2021 (57% [95% CI, 47%-68%]). Reasons for lower COVID-19 vaccine acceptance included higher monthly income, being non-homosexual, history of chronic disease, COVID-19-related medical mistrust, not knowing anyone who died of COVID-19, believing oneself to be immune to COVID-19, general vaccine refusal, negative attitude to the vaccine, concerns about efficacy, safety and side effects, distrust in common sources of vaccine-related information and using social media as a source of information on COVID-19. Conclusion: Among PLHIV, acceptance of COVID-19 vaccine is generally low. A greater emphasis on collaborative efforts between all concerned bodies is needed to boost vaccine acceptance in this population.

show abstract

“…Moreover, Su et al performed a similar survey, but only within the HIV-positive participants, and concluded that the most important factors influencing acceptance were the perception that vaccination is unsafe for HIV-infected people (aOR = 0.082, 95% CI = 0.024–0.282) and the poor efficacy in preventing COVID-19 in HIV-positive persons (aOR = 0.093, 95% CI = 0.030–0.287). Other factors associated with acceptance included Zhuang ethnicity (aOR = 1.653, 95% CI = 1.109–2.465), a highest education level of middle school, high school, or above (aOR = 1.747, 95% CI = 1.170–2.608; aOR = 2.492, 95% CI = 1.326–4.682), and the vaccination having little effect on ART efficacy (aOR = 2.889, 95% CI = 1.378–6.059) [ 22 ]. Therefore, there are many issues that clinicians have to face in order to obtain immunity among the vast majority of the population and break the epidemiological chain of SARS-CoV-2 infections.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland

et al. 2023

View full text Add to dashboard Cite

People living with HIV (PLWH) are a heterogeneous group of immunocompromised persons, yet underrepresented in randomized clinical trials leading to vaccination registration. Detectable HIV viral load and having chronic comorbidities may increase the risk of severe COVID-19 outcomes in this group of patients. We aimed to assess the efficacy and safety of vaccinations against COVID-19 in PLWH. Materials and Methods: We performed a retrospective analysis of medical records of HIV-positive individuals routinely followed up between 1st January 2021 and 30 April 2022 that were at the HIV Outpatient Clinic in Warsaw. The analysis included data on the type and date of administration of subsequent doses of COVID-19 vaccination, adverse vaccine reactions, and the history of SARS-CoV-2 infection. Results: In total, 217 patients were included in the analysis, with a median age of 43 years (IQR: 35.5–51.5 years) and median CD4+ count of 591 cells/uL (IQR: 459.5–745.0 cells/uL). Most of the patients were male (191/217, 88.0%) and were vaccinated with the BNT162b2 vaccine (143/217, 65.9%). None of the patients diagnosed with COVID-19 required hospitalization. Vaccine adverse events (VAE) mostly occurred after the 1st dose (in 33/217 (15.2%)), and none of them were severe or required medical care. Conclusions: In our cohort of patients, vaccination against COVID-19 proved to be safe and effective against a severe course of the disease among people living with HIV. However, vaccination, to a lesser degree, protects against mild SARS-CoV-2 infection. Longer observations are required in order to assess the sustainability of protection against severe COVID-19 in this group of patients.

show abstract

Acceptance of COVID-19 vaccination and influencing factors among people living with HIV in Guangxi, China: a cross-sectional survey

Cited by 14 publications

References 34 publications

COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

COVID-19 vaccination status, side effects, and perceptions among breast cancer survivors: a cross-sectional study in China

COVID‐19 vaccine acceptance among people living with HIV: A systematic review and meta‐analysis

The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland

Contact Info

Product

Resources

About